Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?
TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.
TEM - Tempus AI, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$71.33
DETAILS
HIGH:
$100.00
LOW:
$59.00
MEDIAN:
$64.50
CONSENSUS:
$71.33
UPSIDE:
67.09%
Stock News
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. Following its acquisition of OneOme in November 2025, Tempus has fully integrated these capabilities to expand its comprehensive precision medicine po.
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Tempus AI (NASDAQ: TEM) executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all outstanding shares of Personalis not already owned by Tempus at $16.25
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Personalis, Inc. (NasdaqGM: PSNL) to Tempus AI, Inc. (NasdaqGS: TEM). Under the terms of the proposed transaction, shareholders of Personalis will receive $16.25 per common share. The consideration is reported to be structured as a 100% stock transaction, with Tempus having the option to elect paymen.
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
On Monday, Tempus AI, Inc. (NASDAQ:TEM) agreed to acquire Personalis, Inc. (NASDAQ:PSNL), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities.
Tempus AI, Inc. $TEM Stake Boosted by Amova Asset Management Americas Inc.
Amova Asset Management Americas Inc. raised its stake in Tempus AI, Inc. (NASDAQ: TEM) by 23.4% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 4,326,313 shares of the company's stock after purchasing an additional 821,490 shares during the quarter. Tempus AI accounts for 2.8% of
Cathie Wood's Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks
Tempus AI Inc. (NASDAQ:TEM) investors have a decision to make. Shares of the precision medicine company fell nearly 6% Monday, taking year-to-date losses to 16%, after it announced a $1.5 billion all-stock acquisition of Personalis, Inc. (NASDAQ:PSNL) — a deal that expands its oncology platform but also raises concerns about shareholder dilution ahead of earnings on July 30.
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Tempus AI NASDAQ: TEM executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner.
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B
Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a 28% premium to the unaffected 30-day volume-weighted average price.
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink
Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring. Under the terms of the agreement, Persona.
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B
Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that...
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting. The study was a real-world evaluation of the Paige Prostate Suite, an integral part of the Tempus intelligent diagnostics ecosystem, and its integration into routine clinical workflows. AI-assisted review supported.
Tempus AI: Building Ultimate Healthcare Data Dominance
Tempus AI, Inc. earns a Strong Buy rating due to its transformation into a healthcare data giant with high-margin, rapidly growing data services. TEM's Q1 2026 data segment revenue surged 40% YoY to $87M, with robust bookings and visibility, positioning the segment for $500M+ revenue in 2026. MRD testing volume rose 500% YoY, driven by a highly sensitive, reimbursed test partnership with Personalis, fueling valuable data acquisition for pharma clients.
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.
Tempus to Report Second Quarter 2026 Financial Results on July 30
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The.
Price Targets
Tempus AI Inc (TEM) PT Raised to $65 at Guggenheim
$65.00
(was $57.25)
Subbu Nambi
·
Guggenheim
Tempus AI price target lowered to $64 from $95 at H.C. Wainwright
$64.00
(was $49.86)
Yi Chen
·
H.C. Wainwright
Tempus AI price target lowered to $80 from $90 at BTIG
$80.00
(was $49.86)
BTIG
Tempus AI Inc (TEM) PT Raised to $95 at H.C. Wainwright
$95.00
(was $52.03)
Yi Chen
·
H.C. Wainwright
Tempus AI Inc (TEM) PT Lowered to $60 at Stifel, Firm Highlights 'Solid' Outlook
$60.00
(was $53.83)
Daniel Arias
·
Stifel Nicolaus
Tempus AI initiated with an Outperform at Mizuho
$100.00
(was $56.16)
Bradley Bowers
·
Mizuho Securities
Tempus AI initiated with an Outperform at Baird
$59.00
(was $51.95)
Robert W. Baird
Tempus AI price target lowered to $80 from $95 at Canaccord
$80.00
(was $64.46)
Kyle Mikson
·
Canaccord Genuity
Tempus AI assumed with an Overweight at Morgan Stanley
$85.00
(was $74.07)
Morgan Stanley
Tempus AI Inc (TEM) PT Raised to $105 at BTIG
$105.00
(was $76.06)
Mark Massaro
·
BTIG
Tempus AI Inc (TEM) PT Lowered to $95 at Canaccord Genuity
$95.00
(was $84.49)
Kyle Mikson
·
Canaccord Genuity
Tempus AI price target raised to $105 from $70 at Piper Sandler
$105.00
(was $89.10)
Piper Sandler
Tempus AI initiated with a Buy at Canaccord
$110.00
(was $87.78)
Canaccord Genuity
Tempus AI price target raised to $95 from $80 at Guggenheim
$95.00
(was $78.93)
Guggenheim
Tempus AI initiated with a Buy at H.C. Wainwright
$90.00
(was $78.34)
Yi Chen
·
H.C. Wainwright
Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
$70.00
(was $58.74)
Ryan MacDonald
·
Needham
Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
$60.00
(was $58.74)
Mark Massaro
·
BTIG
Tempus AI price target raised to $60 from $50 at Morgan Stanley
$60.00
(was $48.86)
Morgan Stanley
Tempus AI price target lowered to $55 from $70 at Piper Sandler
$55.00
(was $52.73)
Piper Sandler
Tempus AI Inc (TEM) PT Raised to $70 at Piper Sandler
$70.00
(was $44.95)
David Westenberg
·
Piper Sandler